The Company expects that cash, cash equivalents, and short-term investments as of March 31, 2025, will enable the Company to fund its operating expenses and capital expenditure requirements through the end of 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPP:
- Buy Rating for Rapport Therapeutics: Promising Precision Therapeutics for CNS Disorders
- Rapport Therapeutics initiated with an Outperform at Citizens JMP
- Rapport Therapeutics to present data at 2025 AAN meeting
- Buy Rating Affirmed for Rapport Therapeutics Amid Promising RAP-219 Trials and Strong Financial Position
- Rapport Therapeutics Reports 2024 Financial Results and Progress